

Datasheet: MCA87SBUV445

## **BATCH NUMBER 64635588**

| Description:  | MOUSE ANTI HUMAN CD45:StarBright UltraViolet 445 |  |  |
|---------------|--|--|--|
| Specificity:  | CD45   |  |  |
| Other names:  | LCA  |  |  |
| Format:       | StarBright UltraViolet 445                       |  |  |
| Product Type: | Monoclonal Antibody                              |  |  |
| Clone:        | F10-89-4   |  |  |
| Isotype:      | IgG2a  |  |  |
| Quantity:     | 100 TESTS/0.5ml                                  |  |  |
|               |  |  |  |

# **Product Details**

## **Applications**

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <a href="www.bio-rad-antibodies.com/protocols">www.bio-rad-antibodies.com/protocols</a>.

|                | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry | •   |    |                | Neat               |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

| Target Species  | Human                             |                         | C. I. A. A. A. F I   |
|-----------------|-----------------------------------|-------------------------|----------------------|
| Product Form    | Purified IgG conjugate            | ed to StarBright UltraV | riolet 445 - liquid  |
| Max Ex/Em       | Fluorophore                       | Excitation Max (nm)     | Emission Max (nm     |
|                 | StarBright UltraViolet<br>445     | 347                     | 440                  |
| Preparation     | Purified IgG prepared supernatant | by affinity chromatog   | raphy on Protein A f |
| Buffer Solution | Phosphate buffered s              | aline                   |                      |
| Preservative    | 0.09% Sodium Azide                | (NaN <sub>3</sub> )     |                      |
| Stabilisers     | 1% Bovine Serum Alb               | oumin                   |                      |
|                 | 0.1% Pluronic F68                 |                         |                      |

0.1% PEG 3350 0.05% Tween 20

## Immunogen

Human T lymphocytes.

# **External Database**

Links

**UniProt:** 

P08575 Related reagents

**Entrez Gene:** 

5788 PTPRC Related reagents

#### **Synonyms**

**CD45** 

#### **Fusion Partners**

Spleen cells from immunized BALB/c mice were fused with cells of the mouse NS-1 myeloma cell line.

## **Specificity**

Mouse anti Human CD45 antibody, clone F10-89-4 recognizes the human CD45 cell surface antigen, also known as leucocyte common antigen (LCA). CD45 is a complex molecule existing in a number of isoforms.

Antibodies recognizing a common epitope on all of these isoforms are termed CD45 whilst those recognizing only individual isoforms are termed CD45RA or CD45RO etc.

Mouse anti Human CD45 antibody, clone F10-89-4 reacts with all forms of CD45 expressed by all haematopoietic cells, except erythrocytes, having a higher level of expression on lymphocytes than on granulocytes. It is routinely tested in flow cytometry on human peripheral blood leucocytes.

Mouse anti Human CD45 antibody, clone F10-89-4, has been validated for use on the Genesis Cell Isolation System with the CelSelect Slide<sup>TM</sup> technology.

### Flow Cytometry

Use 5ul of the suggested working dilution to label 10<sup>6</sup> cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.

### References

- 1. Quenby, S *et al.* (1999) Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Human Reprod. 14(9):2386-2391.
- 2. Hauser, P.V. *et al.* (2010) Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. <u>Am J Pathol. 177: 2011-21.</u>
- 3. Mallam, E. *et al.* (2010) Characterization of *in vitro* expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. <u>Mult Scler. 16: 909-18.</u>
- 4. Marrinucci, D. *et al.* (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. <u>J Oncol. 2010: 861341.</u>
- 5. Paul, G. *et al.* (2012) The adult human brain harbors multipotent perivascular mesenchymal stem cells. <u>PLoS One. 7: e35577.</u>
- 6. De Schauwer, C. *et al.* (2012) In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. Cytometry A. 81 (4): 312-23.
- 7. Kazane, S.A. et al. (2012) Site-specific DNA-antibody conjugates for specific and

- sensitive immuno-PCR. Proc Natl Acad Sci U S A. 109: 3731-6.
- 8. Spaas, J.H. *et al.* (2013) Culture and characterisation of equine peripheral blood mesenchymal stromal cells. Vet J. 195 (1): 107-13.
- 9. Sadarangani, A. *et al.* (2015) GLI2 inhibition abrogates human leukemia stem cell dormancy. <u>J Transl Med. 13: 98.</u>
- 10. Gunawardene, P. *et al.* (2015) Association Between Circulating Osteogenic Progenitor Cells and Disability and Frailty in Older Persons: The Nepean Osteoporosis and Frailty Study. <u>J Gerontol A Biol Sci Med Sci. pii: glv190.</u>
- 11. Mohamed Suhaimi, N.A. *et al.* (2015) Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. <u>Mol Oncol. 9 (4):</u> 850-60.
- 12. Ruiz, C. *et al.* (2015) Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol. 12 (1): 016008.
- 13. Gogoi P *et al.* (2016) Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <u>PLoS One.</u> 11 (1): e0147400.
- 14. Gomiero, C. *et al.* (2016) Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology. <u>Vet Res Commun. 40 (1): 39-48.</u>
- 15. Bianchessi, M. *et al.* (2016) Effect of Fibroblast Growth Factor 2 on Equine Synovial Fluid Chondroprogenitor Expansion and Chondrogenesis. <u>Stem Cells Int. 2016</u>: 9364974.
- 16. Branly, T. *et al.* (2017) Characterization and use of Equine Bone Marrow Mesenchymal Stem Cells in Equine Cartilage Engineering. Study of their Hyaline Cartilage Forming Potential when Cultured under Hypoxia within a Biomaterial in the Presence of BMP-2 and TGF-β1. Stem Cell Rev Rep. 13 (5): 611-30.
- 17. GarikipatiV, N.S. *et al.* (2018) Isolation and characterization of mesenchymal stem cells from human fetus heart. <u>PLoS One. 13 (2): e0192244.</u>
- 18. Shishido, S.N. *et al.* (2019) Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <u>J Transl Med. 17 (1): 294.</u>
- 19. Welter, L. *et al.* (2020) Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. <u>Cold Spring Harb Mol Case Stud.</u> 6 (6): a005819.
- 20. Ndacayisaba, L.J. *et al.* (2022) Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones Curr Oncol. 29 (5): 2954-72.
- 21. Shishido, S.N. *et al.* (2022) Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma. <u>Cancers (Basel)</u>. 14 (12): 3007.
- 22. Chai, S. *et al.* (2022) Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol. 6 (1): 41.
- 23. Zhu, J. *et al.* (2022) Sequential Method for Analysis of CTCs and Exosomes from the Same Sample of Patient Blood. ACS Omega. 7 (42): 37581-88.
- 24. Setayesh, S.M. *et al.* (2022) Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. NPJ Breast Cancer. 8 (1): 112.
- 25. Ndacayisaba, L.J. *et al.* (2022) Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. <u>Int J Mol Sci. 23 (21): 13427.</u>
- 26. Qi, E. *et al.* (2023) Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection. EBioMedicine. 90: 104519.
- 27. Seo, J. et al. (2023) Plasticity of circulating tumor cells in small cell lung cancer. Sci

#### Rep. 13 (1): 11775.

28. Setayesh, S.M. *et al.* (2023) Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. <u>NPJ Precis Oncol. 7 (1): 95.</u>

29. Welter, L. *et al.* (2023) Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 15 (15): 3949.

30. Shishido, S.N. *et al.* (2024) Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. NPJ Precis Oncol. 8 (1): 36.

31. Bai, L. *et al.* (2024) Longitudinal tracking of circulating rare events in the liquid biopsy of stage III-IV non-small cell lung cancer patients. Discov Oncol. 15 (1): 142.

32. Shishido, S.N. *et al.* (2024) Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy <u>BJC</u> Reports. 2: 47.

33. Moellerberndt, J. *et al.* (2024) Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells. Front Vet Sci. 11: 1385395.

34. Schmidt, M.J. *et al.* (2024) Polyploid cancer cells reveal signatures of chemotherapy resistance. bioRxiv. Aug 23 [Preprint].

| Storage                          | Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.   |
|----------------------------------|--|
| Guarantee                        | 12 months from date of despatch  |
| Acknowledgements                 | This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts  |
| Health And Safety<br>Information | Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA87SBUV445">https://www.bio-rad-antibodies.com/SDS/MCA87SBUV445</a> 20471 |
| Regulatory                       | For research purposes only   |

# Related Products

## **Recommended Useful Reagents**

HUMAN SEROBLOCK (BUF070A)
HUMAN SEROBLOCK (BUF070B)

North & South Tel: +1 800 265 7376

Worldwide

Tel: +44 (0)1865 852 700

**Europe** Tel: +49 (0) 89 8090 95 21

America Fax: +1 919 878 3751

Fax: +44 (0)1865 852 739

Fax: +49 (0) 89 8090 95 50

 ${\bf Email: antibody\_sales\_us@bio-rad.com}$ 

Email: antibody\_sales\_uk@bio-rad.com

 ${\bf Email: antibody\_sales\_de@bio-rad.com}$ 

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M395181:220321'

## Printed on 12 Dec 2024